Clinical Differences in Patients Infected with Fusobacterium and Antimicrobial Susceptibility of Fusobacterium Isolates Recovered at a Tertiary-Care Hospital in Korea
- PMID: 34635612
- PMCID: PMC8548237
- DOI: 10.3343/alm.2022.42.2.188
Clinical Differences in Patients Infected with Fusobacterium and Antimicrobial Susceptibility of Fusobacterium Isolates Recovered at a Tertiary-Care Hospital in Korea
Abstract
Background: Fusobacterium species are obligately anaerobic, gram-negative bacilli. Especially, F. nucleatum and F. necrophorum are highly relevant human pathogens. We investigated clinical differences in patients infected with Fusobacterium spp. and determined the antimicrobial susceptibility of Fusobacterium isolates.
Methods: We collected clinical data of 86 patients from whom Fusobacterium spp. were isolated from clinical specimens at a tertiary-care hospital in Korea between 2003 and 2020. In total, 76 non-duplicated Fusobacterium isolates were selected for antimicrobial susceptibility testing by the agar dilution method, according to the Clinical and Laboratory Standards Institute guidelines (M11-A9).
Results: F. nucleatum was most frequently isolated from blood cultures and was associated with hematologic malignancy, whereas F. necrophorum was mostly prevalent in head and neck infections. Anti-anaerobic agents were more commonly used to treat F. nucleatum and F. varium infections than to treat F. necrophorum infections. We observed no significant difference in mortality between patients infected with these species. All F. nucleatum and F. necrophorum isolates were susceptible to the antimicrobial agents tested. F. varium was resistant to clindamycin (48%) and moxifloxacin (24%), and F. mortiferum was resistant to penicillin G (22%) and ceftriaxone (67%). β-Lactamase activity was not detected.
Conclusions: Despite the clinical differences among patients with clinically important Fusobacterium infections, there was no significant difference in the mortality rates. Some Fusobacterium spp. were resistant to penicillin G, ceftriaxone, clindamycin, or moxifloxacin. This study may provide clinically relevant data for implementing empirical treatment against Fusobacterium infections.
Keywords: Antimicrobial susceptibility; Clinical difference; Fusobacterium necrophorum; Fusobacterium nucleatum; Fusobacterium species; Korea.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.
Similar articles
-
Clinical characteristics and antimicrobial susceptibility of Fusobacterium species isolated over 10 years at a Japanese university hospital.Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):423-433. doi: 10.1007/s10096-023-04734-2. Epub 2023 Dec 19. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38112966
-
Gram-negative anaerobic bacilli: Their role in infection and patterns of susceptibility to antimicrobial agents. II. Little-known Fusobacterium species and miscellaneous genera.Rev Infect Dis. 1981 May-Jun;3(3):599-626. doi: 10.1093/clinids/3.3.599. Rev Infect Dis. 1981. PMID: 7025153 Review.
-
Frequency, microbial interactions, and antimicrobial susceptibility of Fusobacterium nucleatum and Fusobacterium necrophorum isolated from primary endodontic infections.J Endod. 2008 Dec;34(12):1451-6. doi: 10.1016/j.joen.2008.08.036. Epub 2008 Oct 19. J Endod. 2008. PMID: 19026872
-
Characterization of Fusobacterium isolates from the respiratory tract of white-tailed deer (Odocoileus virginianus).J Vet Diagn Invest. 2014 Mar;26(2):213-20. doi: 10.1177/1040638714523613. Epub 2014 Mar 3. J Vet Diagn Invest. 2014. PMID: 24590666
-
Fusobacterium necrophorum endocarditis Case report and review of the literature.Diagn Microbiol Infect Dis. 2011 Feb;69(2):192-5. doi: 10.1016/j.diagmicrobio.2010.09.014. Diagn Microbiol Infect Dis. 2011. PMID: 21251564 Review.
Cited by
-
Nano-mupirocin as tumor-targeted antibiotic: Physicochemical, immunotoxicological and pharmacokinetic characterization, and effect on gut microbiome.J Control Release. 2024 Sep;373:713-726. doi: 10.1016/j.jconrel.2024.07.045. Epub 2024 Aug 2. J Control Release. 2024. PMID: 39038544
-
Influence of the Microbiome Metagenomics and Epigenomics on Gastric Cancer.Int J Mol Sci. 2022 Nov 9;23(22):13750. doi: 10.3390/ijms232213750. Int J Mol Sci. 2022. PMID: 36430229 Free PMC article. Review.
-
Unveiling the etiology of peritonsillar abscess using next generation sequencing.Ann Clin Microbiol Antimicrob. 2023 Nov 8;22(1):98. doi: 10.1186/s12941-023-00649-0. Ann Clin Microbiol Antimicrob. 2023. PMID: 37940951 Free PMC article.
-
Clinical characteristics and antimicrobial susceptibility of Fusobacterium species isolated over 10 years at a Japanese university hospital.Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):423-433. doi: 10.1007/s10096-023-04734-2. Epub 2023 Dec 19. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38112966
-
Gastrointestinal Variant of Lemierre Syndrome due to Fusobacterium nucleatum: A Case Report.Case Rep Gastroenterol. 2024 Mar 18;18(1):144-152. doi: 10.1159/000536619. eCollection 2024 Jan-Dec. Case Rep Gastroenterol. 2024. PMID: 38501151 Free PMC article.
References
-
- Jorgensen JH, Pfaller MA, et al., editors. Manual of clinical microbiology. 11th ed. ASM Press; Washington: 2015. pp. 967–93.
-
- Kristensen LH, Jensen A, Prag J. Fusobacterium necrophorum: from tonsillitis to Lemierrés syndrome. Ugeskr Laeger. 2009;171:987–90. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous